Icon

DACOGEN (nda021790)- (50MG/VIAL)

DECITABINE OTSUKA
50MG/VIAL
No Yes
Expired 2011-May-02
2013-May-02 None
None No
DACOGEN is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
18 0 16
Total Other Developers 9
Drugs with Suitability No
50MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ** ****** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ***** *** ***** *** (*****) ***. *********** ****** ****** ********** ******, ******, ***********, *******, ***** (***) ***
****** ********* *** ** ****** ******** ******* *********** *-** ** *-**, ************** ************ ***; *****, ***** ********** ****, *********, *********, ************, ********* ******, ***** (***) ***
****** ***** *** ****** ******** ******* *********** *-** ** *-**, ************** ************ ***; *****, ***** ********** ****, *********, *********, ************, ********* ******, ***** (***) ***
****** ****** **** ******* *************** **** *********** *** ********* **, ********, ****** ****, *********** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ******* ****** ***** ******* ****** ************** ***** **., ***. *********** **.* ******* ****, ******** *** ********* *********** ****, ***********, ******* ******, ***** (***) ***
****** ***** ****** ***** ******* ******** ******* ******* *********** **** **.*, *******, ******* ******** ****, ******* ***** *******, ******* ******, ****** ******, *********, ******* ******, ***** (***) ***
****** ***** ****** ****** ****** ************ ******* *** *********** **** **.**,*** & ** ** **, ******* ********** ****** ******, **********, *******, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.